Trial Profile

Randomized study of Taxane vs TS-1 in metastatic or recurrent breast cancer patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel; Paclitaxel
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms SELECT-BC

Most Recent Events

04 Jun 2019 Results of pooled analysis from two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
02 Nov 2016 Results (n=380) analysing impacts of adverse events on health-related quality of life in patients from SELECT BC study, presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
23 Nov 2015 Results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com